Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis

Fig. 1

Mechanism of action of PD-1 and PD-L1 inhibitors (a) PD-1/PD-L1 binding inhibits T cell killing of tumor cells. b Blocking PD-L1 or PD-1 allows T cell killing. c Overview of the mechanism: APC T cell interaction T cell activation (i.e., cytokine secretion, lysis, proliferation, migration to tumor) Tumor microenvironment.

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us